Biopath

Biopath is a specialized company focused on providing innovative medical diagnostic solutions with an emphasis on improving patient outcomes through advanced technology. Founded in 1981 and headquartered in Charenton-le-Pont, France, Biopath is a company that develops diagnostic tests to enhance patient care. Frances Yang, the founder and current CEO, has a background in the healthcare sector and has remained committed to advancing diagnostic capabilities. In October 2018, Biopath was acquired by Unilabs Group Services, a portfolio company of Apax Partners France, though the financial terms of the deal were not disclosed.

Biopath specializes in offering a range of medical diagnostic solutions that aim to improve patient outcomes. Their product portfolio includes advanced diagnostic tests that leverage cutting-edge technology, focusing on enhancing the accuracy and efficiency of patient diagnostics. These offerings are designed for use in various healthcare settings, ensuring that medical professionals have access to reliable tools for patient assessment and treatment planning. In 2018, Biopath reported revenues of USD 70.

90 mn and an EBITDA of USD 17. 62 mn, demonstrating a solid financial performance that supports its operational capabilities and growth potential. Biopath is strategically focused on developing new diagnostic products aimed at enhancing healthcare delivery and patient management. Plans are underway to expand into new markets, with particular interest in regions across Europe and North America by 2022.

The funds from the acquisition by Unilabs Group Services are expected to support the development of these new diagnostic technologies and facilitate entry into targeted geographic markets.